Skip to main content

Table 9 Systematic review of OS outcomes

From: Laparoscopic versus open approach in gastrectomy for advanced gastric cancer: a systematic review

References

Group

Follow-up (mo.)

OS

P

Zhao et al. [18]

L

37 (6–72)

1 y, 87.2%; 3 y, 57.2%; 5 y, 50.3%

NS

O

1 y, 87.1%; 3 y, 54.1%; 5 y 49.2%

Shuang et al. [17]

L

36.5 (23–50)

50 mo., 64%

NS

O

38.5 (27–50)

50 mo., 60%

Scatizzi et al. [16]

L

18 (2–37)

42 mo., 70.91%

0.449

O

18 (7–42)

42 mo., 56.77%

Cai et al. [15]

L

22.1354 (4–36)

40 mo., 67.1%

–

O

40 mo., 53.8%

Chun et al. [20]

L

60.4 (7.0–91.7)

5 y, 91.3%

0.613

O

53.2 (1.0–82.2)

5 y, 88.6%

Chen et al. [19]

L

19 (1–48)

1 y, 91.5%

0.297

O

1 y, 89.8%

Hamabe et al. [21]

L

30.4 (1–60.9)

5 y, 94.4%

0.4877

O

53.5 (1.3–111.3)

5 y, 78.5%

Kim et al. [22]

L

53.7 (8.3–138.1)

5 y, 85.9 %

0.463

O

58.1 (0.3–106.2)

5 y, 83.1%

Moisan et al. [23]

L

28 mo.

3 y, 82.3%

0.557

O

40 mo.

3 y, 86.9

Gordon et al. [25]

L

49.2 (4–146)

5 y, 79.2%

NS

O

5 y, 77.2%

Bo et al. [24]

L

61.2 mo. (6–84 mo.)

5 y, 49.3%

0.756

O

5 y, 46.5%

Shinohara et al. [27]

L

48.8 (25–58.5)

5 y, 68.1 %

0.968

O

5 y, 63.7 %

Lin et al. [26]

L

23.0(12-50 )

1 y, 88.0%

NS

O

1 y, 85.5%

Fang et al. [28]

L

44 (1-82)

5 y, 59%

5 .525

O

5 y, 54%

Zhang et al. [32]

L

38

5 y, 59%

0.523

O

40

5 y, 56%

Hao et al. [33]

L

53.5

5 y, 57.65%

0.22

O

5 y, 53.69%

Li1 et al. [35]

L

–

–

–

O

–

–

Zhang et al. [38]

L

38

5 y, 57%

0.606

O

40

5 y, 50%

Zhang et al. [40]

L

37 (3–60)

1 y, 89.2 %; 3 y, 72.1%; 5 y, 45.7%

NS

O

1 y, 87.4%; 3 y, 68.1%; 5 y, 42.3%

Xu et al. [39]

L

22(3-100)

5 y, 31.3%

0.949

O

5 y, 29.9%

Li3 et al. [42]

L

69(3–120)

5 y, 52.0%

0.805

O

5 y, 53.4%

Xu et al. [49]

L

58 (0–129)

5 y, 51.2%

0.081

O

49.5 (0–104.5)

5 y, 46.7%

Inokuchi et al. [41]

L

62.2 (2.8–149.4)

5 y, 70%

0.96

O

62.2 (4.4–130.4)

5 y, 73%

Park et al. [43]

L

38.2

–

–

O

Chan et al. [45]

L

25

60 mo., 47%

0.233

O

35

60 mo., 39%

Kinoshita et al. [46]

L

3.4 y (1.3–5.0)

5 y, 54.2%

–

O

3.5 y (1.7–5.0)

5 y, 53.0%

  1. OS over survival, DFS disease-free survival, NS not significant, – not report, y year, mo. month